Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors (TALENT STUDY)

Next Previous
Trial Profile

Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors (TALENT STUDY)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Appendiceal cancer; Colon cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms TALENT

Most Recent Events

  • 23 Apr 2023 Results pooled analysis from SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT) published in the European Journal of Cancer
  • 08 Jun 2021 Results of plasma biomarker study assessing proangiogenic profiling (n=85), presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
  • 04 May 2021 Primary endpoint (ORR by central radiology assessment for the GI-NET cohort) has not been met , according to Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top